New guidance released Friday (May 3) on how CMS plans to carry out the next round of its historic drug price negotiation program in Medicare includes a handful of new requirements for how drug makers and various Part D drug dispensing entities must interact to ensure the new maximum fair price (MFP) of a selected drug is made available in 2026 and 2027. The draft guidance marks the start of a new timeline for CMS’ second go at selecting some...